

References

L-88

1. Wang TB, Zhang NL and Wang SH et al. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy. *Genetics and Molecular Research Online Journal*. 2014;13(2):3704-3710.
2. Vinay S, Soria J. ERCC1 as predictor of platinum benefit in non-small-cell lung cancer. *Journal of Clinical Oncology*. 2017;36(4):384-386.
3. Lee S, Falzon M, Blackhall F, Spicer J, et al. Randomized prospective biomarker trial of ERCC1 for comparing platinum and nonplatinum therapy in advanced non-small-cell lung cancer: ERCC1 Trial (ET). *J Clin Onc*. 2017;35(4):402-411.
4. Zhang P, Zue P, Cui S, et al. Different splicing isoforms of ERCC1 affect the expression of its overlapping genes CD3EAP and PPP1R13L, and indicate a potential application in non-small lung cell cancer treatment. *Int J Onc*. 2018;52:2155-2165.
5. Wang X, Zhu X, Zhang, H, et al. ERCC1_202 is a prognostic biomarker in advanced stage non-small cell lung cancer patients treated with platinum-based chemotherapy. *Journal of Cancer*. 2017;8(14): 2846-2853.